Ficonalkib(SY-3505)治疗晚期ALK阳性非小细胞肺癌:一项多中心、开放标签、单臂1/2期研究
该研究为Ficonalkib(SY-3505)的首个人体1/2期试验,纳入127例晚期ALK阳性非小细胞肺癌患者,其中62例在1期。1期确定600 mg每日一次为2期推荐剂量,2期65例接受该剂量。600 mg每日一次组可评估患者客观缓解率为47.5%,基线有可测量脑病灶者颅内客观缓解率为37.5%,耐受性良好。
要点
- 1期剂量递增25-800 mg每日一次,800 mg每日一次出现1例剂量限制性毒性,600 mg每日一次被确立为2期推荐剂量。
- 1期客观缓解率为38.3%(23/60,95%CI 26.1%-51.8%)。
- 600 mg每日一次可评估患者客观缓解率为47.5%(38/80,95%CI 36.2%-59.0%),颅内客观缓解率为37.5%(12/32,95%CI 21.1%-56.3%)。
核心结论
- Ficonalkib(SY-3505)耐受性良好,安全性特征有利,在对既往二代ALK TKI耐药的患者中显示出有前景的疗效。
研究设计与样本
- 该研究为首次人体、多中心、开放标签、单臂1/2期研究(中国临床试验注册中心标识:ChiCTR1900025619;ClinicalTrials.gov标识:NCT05257512),分为1期和2期两部分。
- 1期包括剂量递增阶段(25-800 mg每日一次)和剂量扩展阶段(500 mg每日一次或600 mg每日一次);2期纳入接受2期推荐剂量治疗的患者。
- 主要终点为1期的安全性和2期的客观缓解率。
- 2020年4月21日至2023年8月31日期间共纳入127例晚期ALK阳性非小细胞肺癌患者,其中62例在1期。
主要发现
- Ficonalkib吸收良好且耐受,800 mg每日一次时发生1例剂量限制性毒性事件。
- 治疗相关不良事件发生率为85.5%,19.4%的患者经历大于或等于3级事件。
- 1期客观缓解率为38.3%(23/60,95%CI 26.1%-51.8%),600 mg每日一次被确立为2期推荐剂量。
- 2期共65例患者接受600 mg每日一次Ficonalkib治疗;1/2期合计88例患者接受600 mg每日一次治疗,所有患者均接受过既往二代ALK TKI治疗。
- 在600 mg每日一次组中,90.9%的患者经历治疗相关不良事件,14.8%经历大于或等于3级事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment options for second-generation (2nd-gen) ALK tyrosine kinase inhibitor (TKI)-resistant patients are limited. We evaluated the safety, pharmacokinetics, and efficacy of ficonalkib (SY-3505), a third-generation (3rd-gen) ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer. METHODS: This first-in-human, phase 1/2 study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials.gov identifier: NCT05257512) had two parts. Phase 1 included a dose-escalation phase (25-800 mg quaque die [QD]) and a dose-expansion phase (500 mg QD or 600 mg QD). Phase 2 enrolled patients treated at recommended phase 2 dose. Primary end points were safety in phase 1 and objective response rate (ORR) in phase 2. RESULTS: Between April 21, 2020, and August 31, 2023, a total of 127 patients with advanced ALK-positive non-small cell lung cancer were enrolled, with 62 in phase 1. Ficonalkib was well absorbed and tolerated, with one dose-limited toxicity event occurring at 800 mg QD. Treatment-related adverse events occurred in 85.5% of patients, with 19.4% experienced greater than or equal to grade 3 events. The ORR was 38.3% (23 of 60, 95% confidence interval [CI]: 26.1%-51.8%) in phase 1, and 600 mg QD was established as recommended phase 2 dose. In phase 2, a total of 65 patients received ficonalkib at 600 mg QD. In total, 88 patients received ficonalkib at 600 mg QD in phase 1/2, and all had received prior 2nd-gen ALK TKI treatment. Furthermore, 90.9% of the patients experienced treatment-related adverse events and 14.8% experienced greater than or equal to grade 3 events. The ORR in efficacy-assessable patients who received ficonalkib at 600 mg QD was 47.5% (38 of 80, 95% CI: 36.2%-59.0%), with an intracranial ORR of 37.5% (12 of 32, 95% CI: 21.1%-56.3%) in these patients with measurable brain lesions at baseline. CONCLUSIONS: Ficonalkib (SY-3505) was well tolerated, with favorable safety profiles and promising efficacy in patients resistant to prior 2nd-gen ALK TKI.
引用
- Shi Y, Hu X, Li X, et al. Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study. J Thorac Oncol. 2024. PMID: 38295954. doi:10.1016/j.jtho.2024.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。